Trials / Completed
CompletedNCT03745937
A Study to Evaluate the Safety and Tolerability of MEDI0382 in Overweight and Obese Participants With Type 2 Diabetes Mellitus
A Phase 2a Randomized, Blinded, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of MEDI0382 in Overweight/Obese Subjects With Type 2 Diabetes Mellitus
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- MedImmune LLC · Industry
- Sex
- All
- Age
- 18 Years – 74 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase 2a, randomized, blinded, placebo-controlled study in up to 20 overweight or obese participants with type 2 diabetes mellitus. The participants will participate in the study for approximately 18 weeks, including screening, run-in and treatment periods and a safety follow-up.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MEDI0382 | Subcutaneous dose of MEDI0382 will be up-titrated weekly once daily up to 8 weeks during the uptitration period and thereafter once daily in 3-week TEP. |
| DRUG | Placebo | Subcutaneous dose of placebo matched to MEDI0382 will be administered once daily up to 8 weeks during the up-titration period and thereafter once daily through 3 week TEP. |
Timeline
- Start date
- 2019-01-07
- Primary completion
- 2019-05-28
- Completion
- 2019-05-28
- First posted
- 2018-11-19
- Last updated
- 2020-06-05
- Results posted
- 2020-06-05
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT03745937. Inclusion in this directory is not an endorsement.